Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS)

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics with the potential to restore synapses that could improve the lives of patients worldwide, today ...
Healio

Qlaris Bio initiates trials for potassium channel modulator therapy in glaucoma patients

Please provide your email address to receive an email when new articles are posted on . The Osprey and Apteryx trials will assess QLS-111, a potassium channel modulator, in patients with glaucoma. The ...
Business Wire

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
News Medical

Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators

Variants of the KCNC1 gene impact K v 3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic ...
Fox 5 San Diego

Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of ...